Ocular Comfort and the "Aging" Lens (ERBIUM)

NCT ID: NCT01198600

Last Updated: 2012-08-29

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

78 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-07-31

Study Completion Date

2011-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this trial was to evaluate the factors affecting comfortable contact lens wear and how those factors affect contact lens replacement frequency.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Eligible participants began Phase 1, following either Cycle A or Cycle B, and crossing over to the second cycle after completing the first. After the Phase 1 results were evaluated, eligible participants entered Phase 2. After Phase 2 results were evaluated, participants who consistently reported the highest and the lowest comfort scores entered Phase 3 and were defined as either survivors or strugglers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Refractive Error

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Phase 1: Habitual no Replacement, then Habitual Replacement

Contact lenses per participant's habitual prescription worn for 30 days with no replacement, followed by contact lenses per habitual prescription worn for 30 days with a replacement pair dispensed at Day 28.

Group Type OTHER

Habitual contact lens

Intervention Type DEVICE

Hydrogel or silicone hydrogel contact lens per participant's habitual brand and prescription

Phase 1: Habitual Replacement, then Habitual no Replacement

Contact lenses per participant's habitual prescription worn for 30 days with replacement pair dispensed at Day 28, followed by contact lenses per habitual prescription worn for 30 days with no replacement.

Group Type OTHER

Habitual contact lens

Intervention Type DEVICE

Hydrogel or silicone hydrogel contact lens per participant's habitual brand and prescription

Phase 2: Lotrafilcon B Replacement

Contact lenses worn for 56 days with replacement pair dispensed at Day 28.

Group Type OTHER

Lotrafilcon B contact lens

Intervention Type DEVICE

Commercially marketed silicone hydrogel contact lens

Contact lens cleaning and disinfecting system (ClearCare)

Intervention Type DEVICE

Commercially marketed, hydrogen peroxide-based contact lens care system

Phase 3: Lotrafilcon B Replacement Replacement

Contact lenses worn for 43 days with replacement pair dispensed at Day 1 and Day 28.

Group Type OTHER

Lotrafilcon B contact lens

Intervention Type DEVICE

Commercially marketed silicone hydrogel contact lens

Contact lens cleaning and disinfecting system (ClearCare)

Intervention Type DEVICE

Commercially marketed, hydrogen peroxide-based contact lens care system

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Habitual contact lens

Hydrogel or silicone hydrogel contact lens per participant's habitual brand and prescription

Intervention Type DEVICE

Lotrafilcon B contact lens

Commercially marketed silicone hydrogel contact lens

Intervention Type DEVICE

Contact lens cleaning and disinfecting system (ClearCare)

Commercially marketed, hydrogen peroxide-based contact lens care system

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AIR OPTIX AQUA CLEARCARE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least 17 years of age.
* Ocular exam in the last two years.
* Currently wearing hydrogel or silicone hydrogel contact lenses on a daily wear basis with a monthly replacement schedule.
* Wearing contact lenses at least five days per week for a minimum of 10 hours each day.
* Able to wear lenses in the available power range with a best-corrected visual acuity of at least 20/32 in both eyes.

Exclusion Criteria

* Any ocular disease.
* Systemic condition that may affect a study outcome.
* Using any systemic or topical medications that may affect ocular health.
* Wears lenses on an extended or continuous wear schedule.
* Habitually wears multifocal lenses.
Minimum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Waterloo

OTHER

Sponsor Role collaborator

CIBA VISION

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Desmond Fonn, MOptom FAAO

Role: STUDY_DIRECTOR

University of Waterloo Centre for Contact Lens Research

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Waterloo

Waterloo, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P-373-C-006

Identifier Type: -

Identifier Source: org_study_id